PYC Therapeutics (ASX:PYC) has announced a significant step in its board renewal process, appointing former Woodside chief executive Peter Coleman as its new Independent Non-Executive Chair, effective immediately after the company’s Annual General Meeting on 18 November 2025.
PYC Therapeutics is a clinical-stage biotechnology company developing a new generation of RNA-based precision medicines. The company uses a proprietary drug-delivery platform to improve the potency of RNA therapies for monogenic diseases, where clinical development success rates are highest.
The Perth- and San Francisco-based precision RNA therapeutics company said Mr Coleman brings deep experience in corporate leadership, governance, and mergers and acquisitions. The company said Mr Coleman's expertise will support it through its next growth phase as it advances a pipeline of RNA-based treatments for genetic diseases that currently have no therapies.
“I am excited to join such an innovative company at this critical stage in its development journey,” Mr Coleman said. “The potential to demonstrate patient impact over the coming 24 months is going to create multiple commercial options for PYC, and I look forward to applying my expertise for the benefit of the company and its shareholders.”
Mr Coleman will be issued two million unlisted options, exercisable before November 2028 at $1.80 per share, to align with long-term shareholder value creation.
The appointment follows the decision by PYC’s current Chair, Alan Tribe, not to seek re-election at the AGM. Mr Tribe joined the board in 2018 and oversaw the company’s transformation from a research laboratory into a clinical-stage biotechnology company with multiple programs nearing human efficacy readouts.
The board extended its thanks to Mr Tribe “for his stewardship and leadership” over the past seven years.
As part of the transition, Chief Financial Officer and Co-Company Secretary Andrew Taylor will also step down at the end of the AGM. Kevin Hart, the company’s long-standing secretary, will resume full responsibilities as sole Company Secretary.